(CANC) Tema Oncology - Overview
Etf: Oncology, Pharmaceutical, Biotech, Medical, Equipment
Dividends
| Dividend Yield | 0.06% |
| Yield on Cost 5y | 0.57% |
| Yield CAGR 5y | -63.36% |
| Payout Consistency | 75.7% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 24.1% |
| Relative Tail Risk | -4.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.33 |
| Alpha | 28.11 |
| Character TTM | |
|---|---|
| Beta | 0.686 |
| Beta Downside | 0.598 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.04% |
| CAGR/Max DD | 5.63 |
Description: CANC Tema Oncology January 05, 2026
The Tema Oncology ETF (NASDAQ:CANC) aims to allocate at least 80% of its net assets-including any investment-grade borrowings-to publicly traded companies that generate ≥ 50% of their revenue from oncology products, and it operates as a non-diversified fund.
Key industry metrics that shape CANC’s exposure include a projected 8% CAGR for global oncology drug sales through 2028, driven by rising cancer incidence in aging populations and expanding use of immunotherapies such as CAR-T and checkpoint inhibitors. Recent FDA activity remains a critical catalyst: in the past 12 months, the agency approved 15 new oncology indications, pushing biotech R&D spend to a record $35 billion in the U.S. alone. Additionally, the sector’s valuation is sensitive to reimbursement trends, with Medicare’s oncology bundled payment models expected to tighten profit margins for smaller biotechs.
For a data-rich, independent perspective on how CANC’s holdings align with these drivers, you might explore ValueRay’s analytical platform for deeper quantitative insights.
What is the price of CANC shares?
Over the past week, the price has changed by +2.29%, over one month by +5.83%, over three months by +18.24% and over the past year by +43.25%.
Is CANC a buy, sell or hold?
What are the forecasts/targets for the CANC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 43.2 | 18% |
CANC Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 142.2m USD (142.2m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 142.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 142.2m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.44% (E(142.2m)/V(142.2m) * Re(8.44%) + (debt-free company))
Discount Rate = 8.44% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)